Sorafenib

The US FDA approved this once-daily formulation in November 2003, for the OTC relief of itching due to hives. This product is the first and only FDAapproved, non-drowsy antihistamine to offer OTC itch relief to adults and children 6 years of age who suffer from hives. The US FDA's decision was contingent upon the results of label comprehension studies fielded by Schering-Plough to demonstrate that the label could be properly understood by consumers. Marketing is expected to begin in February 2004.
The adverse events and toxicity produced by sunitinib or sorafenib in the various phase II and phase III trials are summarised in Table 3. The lack of a randomised trial comparing these two agents in similar patient populations makes direct comparisons difficult. However, in the phase II trials with sunitinib and the phase III TARGETs trial with sorafenib, cytokine refractory patients were treated, and therefore some preliminary comparisons are reasonable. As outlined in Table 3, the toxicity profiles of sunitinib and sorafenib are somewhat different. The most common grade three toxicities reported with sunitinib in the phase III trial were fatigue, diarrhea, nausea, hypertension, pancytopenia, and electrolyte abnormalities. In addition, 10% of patients had transient decrease in left ventricular ejection fraction LVEF ; . In this trial, 8% of patients stopped therapy due to adverse events. In the TARGETs trial, the. A. Nanez and K. S. Ramos. Biochemistry and Molecular Biology, University of Louisville, Louisville, KY. The molecular mechanisms governing ontogenesis are regulated by environmental and somatic factors in utero that activate or repress the expression of numerous genetic elements. The aryl hydrocarbon receptor Ahr ; is an important nuclear transcription factor during embryogenesis and throughout maturity in multiple organisms. Environmental chemicals acting as Ahr ligands during embryogenesis deregulate Ahr functions to induce deleterious developmental deficits. The Wilms' Tumor suppressor gene Wt-1 ; encodes a Cis2-His2 zinc finger protein that regu.

Families of the critically ill, particularly their unmet needs, became a focus and impetus for The CHEST Foundation's groundbreaking Critical Care Family Assistance Program CCFAP ; . The Foundation recognized having a loved one as a patient of the ICU as one of the most difficult, traumatic events encountered during a lifetime. Despite the recognition of that intense stress, there were few comprehensive programs for improving the plight of ICU families--until The CHEST Foundation changed that. Partnering with the Eli Lilly and Company Foundation, The CHEST Foundation created the CCFAP in 2002 and began implementing it in various hospital settings across the United States.

Variable CADTYPE Value s ; Format 1 2 3 Format Format N Y Format Format Format Format A D M Format # * OTHER * 1 2 T Format Format Format Format Format # 1 2 3 Format Format 1 2 3 Format Format 1 10 11 Format 1 2 3 Format N U Y Format $DONDTH. Drowning Sudden Infant Death Intracranial Hemorrhage Stroke Seizure Drug Intoxication Asphyxiation Cardiovascular Electrical Gunshot Wound Stab Blunt Injury Gunshot Stab Undetermined None of the Above Unknown Other $DTHCIR. Motor Vehicle Accident Alleged Suicide Alleged Homicide Alleged Child Abuse Non-motor Vehicle Accident None of the Above Unknown Other $YNUNK. No Unknown Yes $YNUNK. $DCOD. Anoxia Cerebrovascular Stroke Head Trauma CNS Tumor Unknown Other $RACEFMT. All Native Amer. Asian Black White Unknown Other All DATE9. 23. $TRIND. Not Applicable Not Done Missing Unknown $SEXFMT. All Unknown Male Female All Value label $CADAV. Referral Only Consented not Recovered Recovered DATE9. $LOCAL. NOT LOCAL LOCAL Type char 3. The oncogenic RET through proteasomal targeting. The reasons for the differences obtained with these two kinase inhibitors is not known, but it has been suggested that PP1 may induce structural perturbations in RET that result in the recruitment of the stress-inducible machinery and subsequent proteasomal degradation 10 ; . If binding of Sorafenib does not induce such perturbations, then this would account for the observed differences in mechanism and time course of receptor degradation. The effect of Sorafenib on the kinase activity of mutant RETV804M was also analyzed. This mutant is associated with the FMTC phenotype and affects the gatekeeper amino acid of the kinase domain. Importantly, mutations at this site have been shown to confer resistance to previously tested drugs 11, 20 ; . Here we demonstrate that mutation of the gatekeeper residue Val804 ; to Met desensitizes the kinase to inhibition by PP1 but has essentially no effect on the inhibition by Sorafenib Fig. 5 ; . Analysis of the RET-PP1 structure Protein Data Bank code 2IVV ; 22 ; indicates that the aliphatic side chain of Val804 packs against the benzyl moiety of PP1; a bulky Met residue could only be accommodated by a shift of position of the PP1 inhibitor, and presumably this weakens dramatically its affinity for the kinase. Intriguingly, the model of the RET Sorafenib complex indicates a similar close contact between the Val804 side chain and the central ring of the inhibitor Fig. 6 ; . To accommodate a Met residue at position 804, the Sorafenib molecule would also be required to shift its position. Because inhibitory potency is maintained, we assume that compensatory new interactions are formed with the protein, possibly facilitated by conformational changes in RET. The different mode of binding of Sorafenib and PP1 to the DFGout and DFGin conformations of RET, respectively, and the more extensive contacts formed between Sorafenib and RET compared with PP1 and RET could account for these differences. In this respect, it is interesting that mutation of the gatekeeper residue Thr674 in the FIP1L1PDGFR oncogene conferred resistance to Gleevec but not to Sorafenib 26 ; . Taken together, the data presented here indicate that Sorafenib is indeed a potent RET kinase inhibitor and points toward its promising therapeutic potential for patients affected with MEN2-related tumors. In particular, the demonstration that Sorafenib is an effective inhibitor of oncogenic RET containing mutations at Val804 indicates that tumors may not be able to acquire resistance to this drug by subsequent somatic mutation in this gatekeeper residue and soriatane. 21. Turner JL, Trauger RJ, Daigle AE, Carlo DJ. HIV-1 immunogen induction of HIV-1 specific delayedtype hypersensitivity: results of a double-blind, adjuvant-controlled, dose-ranging trial. AIDS. 1994; 8: 1429-1435. Trauger RJ, Ferre F, Daigle AE, et al. Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 HIV-1 ; immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells. J Infect Dis. 1994; 169: 1256-1264. Levine AM, Groshen S, Allen J, et al. Initial studies on active immunization of HIV-1 infected subjects using a gp120-depleted HIV-1 immunogen: longterm follow-up. J Acquir Immune Defic Syndr. 1996; 11: 351-364. Moss RB, Ferre F, Levine A, et al. Viral load, CD4 percentage, and delayed-type hypersensitivity in subjects receiving the HIV-1 immunogen and antiviral drug therapy. J Clin Immunol. 1996; 16: 266-271. Moss RB, Wallace MR, Giermakowska WK, et al. Phenotypic analysis of human immunodeficiency virus HIV ; type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen. J Infect Dis. 1999; 180: 641-648. Choi DJ, Dube S, Spicer TP, Slade HB, Jensen FC, Poiesz BJ. HIV type 1 isolate Z321, the strain used to make a therapeutic HIV type 1 immunogen, is intersubtype recombinant. AIDS Res Hum Retroviruses. 1997; 4: 357-361. Dawson JD, Lagakos SW. Size and power of twosample tests of repeated measures. Biometrics. 1993; 49: 1022-1032. Bradley JV. Distribution-Free Statistical Tests. Englewood Cliffs, NJ: Prentice-Hall; 1968. 29. Lan KKG, DeMets DL. Changing frequency of interim analysis in sequential monitoring. Biometrics. 1989; 45: 1017-1020. Chalmers I. Underreporting research is scientific misconduct. JAMA. 1990; 263: 1405-1408. Blumenthal D, Campbell EG, Anderson MS, Causino N, Louis KS. Withholding research results in academic life science: evidence from a national survey of faculty. JAMA. 1997; 277: 1224-1228.
If we get serious about protection of wetlands and waterways and we should ; , then there would be a clear need to put in dams, or cart water to tanks, to allow cattle to drink. And fencing, already far too evident within the park because of current licence management, would become one of the most obvious features in the landscape. The National Park would look like a farm. And the cost, though impossible to estimate meaningfully, would be very large indeed. There are other `possible' options, such as increased supervision of cattle, but the unreliability of this is far higher than the already unreliable fencing option. Security of natural resource values and viability of the park The security of natural resource values is a difficult thing to achieve, given threats of weed invasion, global warming and a range of impacts from feral animals and even visitor use. The most effective way to work towards this is by dedicated conservation protection for the park, under a well developed and respected management plan, we are, on most instances, very supportive of the current plan ; and by resourcing the management of the park to enable achievement of conservation programs. Visitor and local community education is another very important element in such a program. Nothing guarantees compliance with management objectives more than understanding. In this respect, involvement of the local community and tourism interests, as well as conservation groups and scientists, in the development of a new management plan is important. Need we repeat, hard-hooved animals must be removed from the park. There are potential employment opportunities for cattlemen and their families in regard to park management and interpretation, and an investigation of proposals for wild horse management in Kosciuszko National Park could be very constructive here. Possible future options for cattle grazing in the ANP There are none. We note, however, that the majority of the public land grazing licences in the High Country region are outside of the park. The VNPA takes no issue in this instance with "forest grazing" licences. ; Opportunities for maximizing natural, economic and cultural values The single greatest opportunity for maximizing natural, economic and cultural values of the park and the region, is the formation of a single great Australian Alps National Park, encompassing all contiguous parks currently under the Australian Alps National Parks Memorandum of Understanding MOU ; . Such a park would be managed by existing agencies, under existing State and Territory legislation, with little change. Significantly, however, the MOU should be upgraded to a cross-border Management Agreement. More information on this proposal, and a proposed management structure, can be found on the website onebigpark , hosted by the National Parks Associations of NSW, the ACT and Victoria and sparfloxacin.
RESULTS Sorafenib-mediated lethality is independent of MEK ERK pathway inactivation. We previously reported that exposure to sorafenib resulted in a time- and dose- dependent inactivation of ERK1 2 in several human leukemia cell types 45 ; . Western blot analysis revealed that sorafenib-mediated ERK1 2 dephosphorylation correlated closely with MEK1 2 dephosphorylation Fig. 1A ; . To investigate the role of MEK1-2 ERK1-2 inactivation in.
Hand-Foot syndrome: Hand-Foot Syndrome, which is also known as Palmar-Plantar Erythrodysesthesia - PPE, is a side effect, which can occur with some chemotherapy. For example, Capecitabine Xeloda ; , 5-Fluorouracil 5FU ; , continuous-infusion of Doxorubicin, Liposomal Doxorubicin Caelyx ; , Sunitinib Sutent ; and Sorafenib Nexavar ; can cause this reaction in some patients. This syndrome is characterized by redness, tenderness, and possibly peeling of the palms and soles. The areas affected can become dry and peel, with numbness or tingling developing. Hand-foot syndrome can be uncomfortable and can interfere with your ability to carry out normal activities. Steps to prevent Hand-Foot syndrome: For the first 7 days after your chemotherapy infusion or at any time while you are taking oral chemotherapy, following the suggestions below may help prevent and ease the symptoms of sore skin: Apply a moisturizer to hands and feet liberally and often, especially in all creases. Suggestions for creams are: Bag Balm, Udder Cream, Lanolin creams, Aveeno, and Lubriderm. ; Avoid exposure of hands and feet to heat such as hot water. Bathe or shower in warm water. Soak hands and or feet in basins of cold water for 15 minutes 3 to 4 times per day if possible. If you are receiving treatment with liposomal doxorubicin every 3-4 weeks, you only need to follow these instructions for the week following each treatment. ; Avoid activities that cause rubbing of skin surfaces or even slight pressure on hands, such as vigorous washing, clasping or clapping of hands, gripping tools or appliances, typing, playing musical instruments and driving. Do not apply tight dressing or adhesive tape to skin, such as band-aids. Before the start of treatment, treat your feet to a pedicure if you have a preexisting buildup of hard skin and calluses on your feet Sit or lie on padded surfaces of chairs or mattresses. Raise legs whenever possible with cushions. Place a pillow between knees or wear pajamas, if rubbing of legs occur during sleep. Avoid any unnecessary walking, jogging or vigorous exercise. Wear loose fitting clothes and loose fitting comfortable shoes with cushioned soles. Do not walk on bare feet and spectinomycin. Sorafenib Nexavar ; is not recommended for use within NHS Scotland for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alfa or interleukin-2 based therapy or are considered unsuitable for such therapy. docetaxel Taxotere ; injection concentrate in combination with cisplatin and 5-fluorouracil is not recommended for use within NHSScotland for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease. mitotane Lysodren ; is not recommended for use within NHS Scotland for the symptomatic treatment of advanced unresectable, metastatic or relapsed ; adrenal cortical carcinoma. The effect of mitotane on non-functional adrenal cortical carcinoma is not established. natalizumab Tysabri ; is not recommended for use within NHS Scotland as single disease modifying therapy in highly active relapsing remitting multiple sclerosis RRMS ; for the following patient groups; patients with high disease activity despite treatment with beta-interferon and in patients with rapidly evolving severe RRMS. rasagiline Azilect ; is not recommended within NHS Scotland for the treatment of idiopathic Parkinson's disease as adjunct therapy with levodopa ; in patients with end of dose fluctuations. rasagiline Azilect ; is not recommended within NHS Scotland for the treatment of idiopathic Parkinson's disease as monotherapy without levodopa ; . lanreotide Somatuline LA ; is not recommended for use within NHSScotland for the treatment of thyrotrophic adenomas when the circulating level of thyroid stimulating hormone remains inappropriately high after surgery and or radiotherapy. pregabalin Lyrica ; is not recommended for use within NHSScotland for generalised anxiety disorder in adults.

PDGFR, c-kit and FLT-3. Preclinical studies showed antitumor activity in various malignancies, including leukemia, breast and lung cancer models[117-119]. In a phase study, the recommended dose for sunitinib was determined to be 50 mg d on a "4-wk-on 2-wk-off " schedule[120]. The toxicities include hypertension, thrombocytopenia, neutropenia, diarrhea, hair and skin changes. Sunitinib is being tested in HCC and in combination with irinotecan and cetuximab in previously treated metastatic colorectal cancer[121-123]. Of the anti-angiogenic agents discussed, bevacizumab proved to be an exceptionally efficacious agent in colorectal cancer when combined with conventional cytotoxic agents. However, this monoclonal antibody failed to achieve the clinical benefit expected in pancreatic cancer in combination therapy. More excitingly, sorafenib becomes the first chemotherapeutic agent to achieve significant clinical benefit in HCC Table 2 and spiriva.
Expression of retinoic acid-inducible gene-I in lupus nephritis K. Suzuki, T. Imaizumi, K. Tsugawa, E. Ito and H. Tanaka Cinacalcet modifies the pH of solutions in vitro: possible implications for gastro-intestinal side effects in vivo ` M. Buemi, G. Coppolino, A. Sturiale, I. Villari, E. Crasci, S. Campo, L. Nostro, C. Aloisi and A. Villari Interstitial nephritis in a patient taking sorafenib H. Izzedine, I. Brocheriou, O. Rixe and G. Deray.

IL-2 Indication: for extremely selected patients and must be delivered in specialized treatment centre Patients failed interferon or are intolerant to first line TKI therapy Sorafenib Indication: second line therapy after cytokine failure based on superior activity comparing to BSC in randomized phase III trial. Dose and Schedule: starting dose at 400mg twice daily orally continuously. Each treatment cycle is 6-week in duration. Patient Management: physician must be aware of the toxicity profile of sorafenib and follow patients accordingly with experienced nursing support. Dose must be modified per individual's toxicity profile. Patient may be assessed every cycle for tolerance. Interval may be lengthened after 2 cycles if clinically appropriate. Efficacy assessment: imaging involved sites q2cycles initially then as clinically indicated. Patients responding with either stable disease or an objective response may continue therapy. Treatment is to be continued until disease progression or patient intolerance and ssd. More than 30 years after the discovery of human hepatitis B virus HBV ; this virus remains to be one of the major global health problems. In infected adolescents or adults, 5%-10% will lead to a chronic carrier state, whereas in infected neonates up to 90% develop chronicity. It is estimated that about 370 million people are chronic carriers of HBV worldwide. In many regions of the world, chronic HBV infection is still the major cause of liver cirrhosis and hepatocellular carcinoma. During the last 30 years, many steps of the viral life cycle have been unravelled, mainly due to cloning, sequencing and expression of the genomic DNA extracted from HBV virions. This has lead to the development of a safe and efficient vaccine and sensitive tests for HBV surface protein HBsAg ; allowing reliable diagnosis and screening of blood products. More recently, a growing number of reverse transcriptase inhibitors have been developed. However, together with these improvements new deficiencies in prevention and cure of HBV infections are becoming apparent. Although HBV is a DNA virus, it is highly variable under immunity or drug induced selection pressure, resulting in vaccine-related escape mutants and drug resistance. To overcome these challenging problems new antivirals and optimised vaccines have to be developed. Dana Hilt, M.D., Senior VP of Clinical Development and Chief Medical Officer. Ms. Hilt joined the Company in April 2006. She was previously employed by Ascend Therapeutics as Senior VP of Drug Development and Chief Medical Officer from 2002 to 2006; and VP of Clinical Research and Chief Medical Officer for Guilford Pharmaceuticals from 1998 to 2002. She received a B.S. Chemistry ; from the University of Maine and an M.D. from Tufts University School of Medicine. Jeffrey E. Young, VP of Finance, Chief Accounting Officer and Treasurer. Mr. Young has been employed by the Company since 2005. He previously was employed by PerkinElmer, Inc., a life science company, in several financial management positions. From 1996 to 2003, he worked for PricewaterhouseCoopers LLP. He is a CPA and received a B.S.B.A. from Georgetown University. Board of Directors: Robert H. Zeiger Chairman ; , Frank E. Thomas, Christopher Walsh, Ph.D., Richard W. Dugan, Nicholas Galakatos, Ph.D., Jean George, Christopher Mirabelli, Ph.D., James B. Tananbaum, M.D., H. Shaw Warren, M.D and stadol. Sorafenib was a potent inhibitor of CRAF and wild-type and mutant V600E ; BRAF with inhibitory concentration IC50s ; of 6 nM, 22 nM and 38 nM, respectively. Sorafenib was also a potent inhibitor of several RTKs linked to tumour progression, including Flt-3, c-Kit, VEGFR2, VEGFR3, and PDGFR-. Sorafenib did not inhibit MEK-1, ERK-1, EGFR, HER2 NEU, c-MET, PKA, PKB, IGFR1, Cdk-1 cyclin B, PIM-1, GSK 3-b, CK-2, PKC-, PKC-, or PKC- at concentrations up to 10 The in vivo anti-tumour efficacy of sorafenib, administered as a single daily oral treatment, has been studied against non-renal tumour xenograft models using athymic mice. In each model, sorafenib was administered p.o. once a day for 9 days starting when all animals in an experiment had established tumours tumour weight of approximately 100 mg ; . All doses are expressed as free base equivalents irrespective of the form of compound administered free base or the tosylate salt ; . The tumour cells were implanted sc into the flank region of female athymic mice NCr-nu nu ; . Sorafenib demonstrates anti-tumour efficacy as a single agent against a broad range of human tumour xenografts including the HCT-116 64%TGI at 30mg kg dose free base ; , DLD-1 66%TGI at 30mg kg dose free base ; , Colo205 66% TGI at 30mg kg dose free base ; , and HT-29 colon tumours 21 ; 71% TGI at 30mg kg dose free base ; , the NCI-H460 56% TGI at 30mg kg dose free base ; , and A549b 60% TGI at 30mg kg dose free base ; NSCLC, the MDA-MB-231 92% TGI at 30mg kg dose free base ; and MX-1 51% TGI at 30mg kg dose free base ; mammary tumours, the MiaPaCa-2 pancreatic tumour 66% TGI at 30mg kg dose free base ; , the MV4; 11 AML 84% TGI at 3mg kg dose free base ; , LOX IMVI melanoma 52% TGI at 30mg kg dose free base ; , and the SK-OV-3 64% TGI at 30mg kg dose free base ; ovarian tumour. The percent tumour growth inhibition TGI ; calculated as 1-T C ; * 100, where T and C represent the mean size of the treated T ; and control C ; tumours on the day after the last dose of sorafenib in each experiment. Sorafenib exhibited anti-tumour efficacy against tumour models that express either mutated k-ras DLD-1, Mia-PaCa-2 ; or BRAF Colo-205, HT-29 ; . Sorafenib showed efficacy against the MDAMB-231 model that exhibits activating mutations of both genes. Sorafenib was also effective against the SK-OV-3 human ovarian tumour line that contains a wild-type ras and BRAF but overexpresses both the EGF and Her2 growth factor receptors. These receptors also signal through the RAS RAF MEK pathway. The anti-tumour efficacy of sorafenib against renal tumour has been studied using female athymic mice NCr-nu nu ; . The studied xenograft models were the A498 human renal cell cancer model, the CAKI-1 human renal tumour model and the RENCA murine renal cell cancer model. In the RENCA model growth inhibition ranging from 30% to 84% was observed following oral administration of doses from 7.5 mg kg day to 90 mg kg day. Preliminary anti-tumour efficacy studies were also conducted against the A498 and CAKI-1 human renal tumour xenograft models in athymic mice. Growth of CAKI-1 tumours was not significantly p 0.8074 ; inhibited by sorafenib at dose levels up to 60 mg kg. The mechanism of action of sorafenib was investigated ex vivo in multiple tumour models including HT-29, DLD-1, HCT-116, and Colo-205 colon tumour models, the MDA-MB-231 breast tumour model, and the Mia-PaCa-2 pancreatic tumour model 21 ; . In each study, animals bearing approximately 200 mg size tumours were treated with sorafenib 30-60 mg kg dose ; for 5 days. Tumours were then collected 3 hours after the final dose and evaluated for modulation of ERK phosphorylation by Western staining and or by immunohistochemistry IHC ; to assess the effect of sorafenib on signaling through the RAF MREK ERK pathway. Tumour samples in some models were also stained with a goat polyclonal antibody against CD31 and the microvessel density was assessed by image analysis to measure the inhibition of neovascularization. An inhibition of the RAF MEK ERK pathway in HT-29, DLD-1, HCT-116, and MDA-MB-231 tumour models but not in Colo-205 or Mia-PaCa-2 tumours was demonstrated. Analysis of the phosphoprotein values in the MDA-MB-231 model showed that RAF MEK ERK phosphorylation was reduced along with six other proteins BTK, CDK1, Ekt BMX, MAPK1, p38, src and Zap70 RMC-01274 ; . Among these the CDK1 also had lower levels of phosphorylation in LOX cells in vitro MRC-01275 ; . In addition, the phosphorylation state of one protein, GSK3 was significantly upregulated. Anti-angiogenetic effects and sorafenib.

Platelets may decrease to 30, 000 L in patients with thrombocytopenia, but medical intervention typically is not required. Onset of laboratory abnormalities usually occurs during the first cycle; it may appear by Day 14 but is most significant on Day 28. Abnormalities generally do not progress from cycle to cycle, but can recur in subsequent cycles. Abnormal laboratory values resolve during treatment breaks, but may take up to 3 weeks to reach grade 2, at which point treatment may be restarted Appendix C ; . Growth factors are generally not necessary for patients receiving multitargeted agents, although patients with anemia may be treated with darbepoetin alfa or epoetin alfa. An oral phosphate supplement can be given for hypophosphatemia. Patients who develop grade 3 or 4 neutropenia or thrombocytopenia during a cycle of sunitinib therapy should be evaluated on Day 1 of the next drug cycle. If the laboratory values have not reached grade 2, the drug should be withheld another week. Likewise, sorafenib should be withheld until laboratory abnormalities have stabilized or have reached grade 2. Patients should be reassured that the drug is being withheld temporarily to allow them time to recover, and will be restarted as soon as they reach threshold laboratory values and stanozolol. All 137 couples involved in this prospective study were referred to our IVF unit because of male subfertility. In 26 cases an additional tubal factor could be diagnosed. The mean age of all women was 32.2 T 4.8 years range 2140 years ; . During the 2-month period of evaluation all. A Light and Electron Microscopic Study. Gritzka TL, Fry LR, Cheesmati RL atid LaVigtie A . Articular Collagenous Tissue, The Immunofluorescent and stelazine.

Causes of respiratory muscle weakness after cardiac surgery are multifactorial and include sepsis, phrenic nerve injury, and poor nutritional status. Hypercalcemia is not a cause. Hypocalcemia, however, would cause muscle weakness and soriatane.

Sorafenib dosage